CD4 and neoplasm: The significance of the demonstration that nivolumab causes an increase in the proportion of CD4+ cells that expressed Foxp3 within the peripheral blood compartment remains unclear since most of the existing literature has focused on CD4+FoxP3+ population within the tumor infiltrating lymphocytes.